Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.38 |
| ▸ | CSF1R | P07333 | 4/20 | 0.38 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30427560 | 1.00 | PARP1 (0.39) | PARP1GRM2CSF1RGPR52SMN1; SMN2 | |
| SCHEMBL30428268 | 0.91 | GRM2 (0.39) | GRM2CSF1RGPR52SMN1; SMN2MEN1 | |
| SCHEMBL21873618 | 0.91 | GRM2 (0.39) | GRM2CSF1RGPR52SMN1; SMN2MEN1 | |
| SCHEMBL21873488 | 0.85 | SLC5A1 (0.39) | SMN1; SMN2RAB9A | |
| SCHEMBL30429049 | 0.85 | SLC5A1 (0.39) | SMN1; SMN2RAB9A | |
| SCHEMBL21935399 | 0.85 | ADORA2A (0.43) | CHRNA7CHRM1KCNH2NPC1RAB9A | |
| SCHEMBL21935658 | 0.84 | ADORA2A (0.42) | SMN1; SMN2KMT2ACHRNA7CHRM1 | |
| SCHEMBL31668954 | 0.82 | CHRM1 (0.54) | CHRM1 | |
| SCHEMBL21873403 | 0.82 | CHRM1 (0.54) | CHRM1 | |
| SCHEMBL21873484 | 0.82 | CHRM1 (0.54) | CHRM1KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12378256-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-08-05 | — | — | US | disclosed |
| EP-3643718-B1 | HETEROCYCLIC COMPOUND AND ITS USE AS POSITIVE ALLOSTERIC MODULATOR OF THE CHOLINERGIC MUSCARINIC M1 RECEPTOR. | TAKEDA PHARMACEUTICALS CO (JP) | 2023-07-26 | — | — | EP | disclosed |
| US-11236099-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-02-01 | — | — | US | disclosed |
| US-20220017530-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-01-20 | — | — | US | disclosed |
| US-20210139491-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-05-13 | — | — | US | disclosed |
| EP-3643718-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2020-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017530-A1 | HETEROCYCLIC COMPOUND | SLC10A2, ALPI, VIP | PARP1 4620/4885GRM2 2865/4885CSF1R 4070/4885 |
| US-12378256-B2 | Heterocyclic compound | SLC10A2, ALPI, VIP | PARP1 4620/4885GRM2 2865/4885CSF1R 4070/4885 |
| US-20210139491-A1 | HETEROCYCLIC COMPOUND | SLC10A2, ALPI, VIP | PARP1 4620/4885GRM2 2865/4885CSF1R 4070/4885 |
| US-11236099-B2 | Heterocyclic compound | SLC10A2, ALPI, VIP | PARP1 4620/4885GRM2 2865/4885CSF1R 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.